Viz HCM vs Zio XT ECG Monitoring System

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Viz HCM
by Viz.ai
VS
Zio XT ECG Monitoring System
by iRhythm Technologies

AI Verdict

Viz HCM focuses on real-time AI analysis of existing ECGs to detect Hypertrophic Cardiomyopathy and streamline care coordination. In contrast, the Zio XT ECG Monitoring System provides continuous, long-term ambulatory cardiac monitoring via a wearable biosensor for comprehensive arrhythmia detection. While both leverage AI for cardiac diagnosis, Viz HCM targets a specific condition and workflow optimization, whereas Zio XT offers extended diagnostic data capture for a broader range of arrhythmias.

Choose Viz HCM if…

Choose Viz HCM if your hospital system requires real-time, AI-powered ECG analysis for the rapid detection of suspected Hypertrophic Cardiomyopathy within an acute care setting. This tool is ideal for streamlining cardiac care coordination, ensuring patients with potential HCM are quickly identified and directed to appropriate specialists, thereby significantly reducing diagnosis and treatment initiation times.

View Viz HCM →

Choose Zio XT ECG Monitoring System if…

Choose the Zio XT ECG Monitoring System if you need a convenient, long-term ambulatory cardiac monitoring solution for patients in an outpatient setting. This wearable biosensor is best suited for detecting intermittent arrhythmias over an extended period (up to 14 days), offering high patient compliance and detailed data for comprehensive diagnosis without the need for external leads.

View Zio XT ECG Monitoring System →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Viz HCM Zio XT ECG Monitoring System
Pricing Unknown Contact for pricing
Deployment Unknown Cloud-based (AWS EC2 platform), no on-premise hardware required.
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Cleared AI-estimated Yes AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Zio XT ECG Monitoring System

Zio XT offers superior patient usability with its wearable, leadless, and water-resistant biosensor, promoting high patient comfort and compliance for continuous monitoring. While Viz HCM streamlines clinician workflows, Zio XT's design directly enhances the patient experience, which is crucial for effective remote monitoring.

Clinical Value

Viz HCM

Viz HCM provides significant clinical value by using AI to detect suspected Hypertrophic Cardiomyopathy (HCM) from routine ECGs, significantly reducing diagnosis time for a serious and often underdiagnosed condition. This proactive detection and accelerated care coordination for HCM, supported by clinical validation, offers a high impact on patient outcomes.

Pricing & Value

Zio XT ECG Monitoring System

Zio XT demonstrates more quantified value through documented reductions in outpatient appointments, avoided implantable loop recorder (ILR) insertions, and decreased operational costs compared to traditional monitoring methods. While both have clear reimbursement pathways, Zio XT provides more concrete examples of direct cost and time savings for healthcare systems.

Enterprise Readiness

Viz HCM

Viz HCM exhibits stronger enterprise readiness with its cloud-based platform designed for seamless integration into existing hospital IT systems, including EHR and PACS. It boasts deployment in over 1,800 hospitals across the U.S., including leading institutions, demonstrating proven large-scale adoption and integration capabilities.

Innovation

Viz HCM

Viz HCM showcases greater innovation by creating a new regulatory category for cardiovascular machine learning-based notification software and being the first company to receive CMS reimbursement for AI in this space. Its real-time AI-powered ECG analysis for proactive disease detection and care coordination represents a novel application of AI in clinical workflow.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer specific details regarding the availability or quality of support and documentation for either Viz HCM or Zio XT. Therefore, it is not possible to distinguish between the two tools on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Viz HCM Zio XT ECG Monitoring System
Company Viz.ai iRhythm Technologies
Primary Detection Target Suspected Hypertrophic Cardiomyopathy (HCM) Arrhythmia detection and diagnosis
Key Technology/Methodology AI-powered ECG analysis for HCM detection, real-time disease detection, mobile-based alerts, automated patient direction Wearable single-lead ECG biosensor, continuous ambulatory cardiac monitoring, FDA-cleared deep-learned AI algorithm, cloud-based software platform (ZEUS)
Monitoring Duration/Type Real-time ECG analysis Continuous ambulatory cardiac monitoring for up to 14 days
Categories Cardiology AI, Clinical Decision Support & Reference Cardiology AI, Wearables & Remote Monitoring (RPM)
Specialties Cardiology, Emergency Medicine, Hospital Medicine Cardiology, Emergency Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Viz HCM and Zio XT ECG Monitoring System.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Viz HCM is an FDA-cleared AI tool specifically focused on detecting suspected Hypertrophic Cardiomyopathy (HCM) using real-time ECG analysis and coordinating cardiac care. In contrast, the Zio XT ECG Monitoring System offers continuous cardiac monitoring for up to 14 days to detect and diagnose various cardiac arrhythmias.
Viz HCM utilizes AI-powered real-time ECG analysis integrated into hospital IT systems to detect suspected HCM from 12-lead ECGs. The Zio XT employs a wearable, single-lead ECG biosensor for continuous ambulatory monitoring for up to 14 days, with data analyzed by an FDA-cleared deep-learned AI algorithm and expert review.
Viz HCM has CMS reimbursement available for CPT codes 0764T and 0765T, with a national payment rate of $128.90 effective January 1, 2025. For the Zio XT, US Medicare rates for CPT codes 93247 (greater than 7 days up to 15 days) and 93243 (greater than 48 hours up to 7 days) were proposed at approximately $229-$260.35.
Viz HCM is a cloud-based platform designed for seamless integration into hospital IT systems, including EHR and PACS, to streamline cardiac care coordination and clinical workflows. The Zio XT is also cloud-based (AWS EC2 platform) and offers EHR integration to streamline ordering and reporting workflows, requiring no on-premise hardware.
Viz HCM provides real-time disease detection from electrocardiograms for suspected Hypertrophic Cardiomyopathy. In contrast, the Zio XT ECG Monitoring System offers continuous ambulatory cardiac monitoring for an extended period of up to 14 days.
Viz HCM focuses on mobile-based alerts and automated direction of patients to appropriate care specialists, aiming to significantly reduce time to diagnosis and treatment for HCM. The Zio XT features a wearable biosensor with no external leads or wires for enhanced patient comfort, is water-resistant for normal daily activities, and includes a patient-activated button for symptomatic event logging, contributing to high patient compliance.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Viz HCM or Zio XT ECG Monitoring System

Backers

Who funded each tool's parent company.

Viz HCM

Zio XT ECG Monitoring System

AI Tool Finder
AI-powered search. Results may not be comprehensive.